儿科指南

订阅

MedSci主页 / 所有栏目 / 儿科指南

儿科用药临床药理学研究指导原则（征求意见稿）

2020-09-01 国家药品监督管理局药品审评中心（CDE） CDE

为满足我国儿童药物研发及注册需要，鼓励采用新技术、新方法开展儿童用药临床试验，进一步明确儿科用药临床药理学技术要求，我中心组织起草了《儿科用药临床药理学研究指导原则（征求意见稿）》，现公开征求意见。欢

中文标题：

儿科用药临床药理学研究指导原则（征求意见稿）

发布机构：

国家药品监督管理局药品审评中心（CDE）

发布日期：

2020-09-01

简要介绍：

为满足我国儿童药物研发及注册需要，鼓励采用新技术、新方法开展儿童用药临床试验，进一步明确儿科用药临床药理学技术要求，我中心组织起草了《儿科用药临床药理学研究指导原则（征求意见稿）》，现公开征求意见。欢迎各界提出宝贵意见和建议，并请及时反馈给我们。
       征求意见时限为自发布之日起1个月。
       请将您的反馈意见发到以下联系人的邮箱：
       联系人：韩鸿璨
       联系方式：hanhc@cde.org.cn
       感谢您的参与和大力支持。
                                                                                                                           国家药品监督管理局药品审评中心
                                                                                                                                         2020年9月1日

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=《儿科用药临床药理学研究指导原则（征求意见稿）》.docx)] GetToolGuiderByIdResponse(projectId=1, id=efaa91c001969610, title=儿科用药临床药理学研究指导原则（征求意见稿）, enTitle=, guiderFrom=CDE, authorId=0, author=, summary=为满足我国儿童药物研发及注册需要，鼓励采用新技术、新方法开展儿童用药临床试验，进一步明确儿科用药临床药理学技术要求，我中心组织起草了《儿科用药临床药理学研究指导原则（征求意见稿）》，现公开征求意见。欢, cover=, journalId=0, articlesId=null, associationId=1936, associationName=国家药品监督管理局药品审评中心（CDE）, associationIntro=国家药品监督管理局药品审评中心（CDE）, copyright=0, guiderPublishedTime=Tue Sep 01 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">为满足我国儿童药物研发及注册需要，鼓励采用新技术、新方法开展儿童用药临床试验，进一步明确儿科用药临床药理学技术要求，我中心组织起草了《儿科用药临床药理学研究指导原则（征求意见稿）》，现公开征求意见。欢迎各界提出宝贵意见和建议，并请及时反馈给我们。</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 征求意见时限为自发布之日起1个月。</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 请将您的反馈意见发到以下联系人的邮箱：</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 联系人：韩鸿璨</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 联系方式：hanhc@cde.org.cn</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 感谢您的参与和大力支持。</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 国家药品监督管理局药品审评中心</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2020年9月1日</span></p> <p>&nbsp;</p>, tagList=[], categoryList=[CategoryDto(categoryId=18, categoryName=儿科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=248, categoryName=真实世界研究, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指导原则, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2451, appHits=155, showAppHits=0, pcHits=503, showPcHits=2296, likes=3, shares=23, comments=6, approvalStatus=1, publishedTime=Fri Sep 11 16:49:00 CST 2020, publishedTimeString=2020-09-01, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Fri Sep 11 16:48:33 CST 2020, updatedBy=4754896, updatedName=fbzhang, updatedTime=Fri Jan 05 11:31:21 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=《儿科用药临床药理学研究指导原则（征求意见稿）》.docx)])
《儿科用药临床药理学研究指导原则（征求意见稿）》.docx
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=977501, encodeId=1a139e750161, content=想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ed95476566, createdName=ms2000000663115913, createdTime=Mon Jun 28 09:37:33 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977500, encodeId=70879e7500df, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ed95476566, createdName=ms2000000663115913, createdTime=Mon Jun 28 09:37:03 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892726, encodeId=39d8892e2681, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/ce079fd0944b4af0896c4bdb2d547ac3/73f2f6c2202b43ceb43dd2354f7f73e6.jpg, createdBy=dfab5426678, createdName=ms2000001622015603, createdTime=Sat Oct 17 22:17:04 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886689, encodeId=ead688668900, content=g, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e855419670, createdName=ms4000001311767518, createdTime=Sat Sep 19 17:33:42 CST 2020, time=2020-09-19, status=1, ipAttribution=)]
    2021-06-28 ms2000000663115913

    想学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=977501, encodeId=1a139e750161, content=想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ed95476566, createdName=ms2000000663115913, createdTime=Mon Jun 28 09:37:33 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977500, encodeId=70879e7500df, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ed95476566, createdName=ms2000000663115913, createdTime=Mon Jun 28 09:37:03 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892726, encodeId=39d8892e2681, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/ce079fd0944b4af0896c4bdb2d547ac3/73f2f6c2202b43ceb43dd2354f7f73e6.jpg, createdBy=dfab5426678, createdName=ms2000001622015603, createdTime=Sat Oct 17 22:17:04 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886689, encodeId=ead688668900, content=g, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e855419670, createdName=ms4000001311767518, createdTime=Sat Sep 19 17:33:42 CST 2020, time=2020-09-19, status=1, ipAttribution=)]
    2021-06-28 ms2000000663115913

    积分

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=977501, encodeId=1a139e750161, content=想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ed95476566, createdName=ms2000000663115913, createdTime=Mon Jun 28 09:37:33 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977500, encodeId=70879e7500df, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ed95476566, createdName=ms2000000663115913, createdTime=Mon Jun 28 09:37:03 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892726, encodeId=39d8892e2681, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/ce079fd0944b4af0896c4bdb2d547ac3/73f2f6c2202b43ceb43dd2354f7f73e6.jpg, createdBy=dfab5426678, createdName=ms2000001622015603, createdTime=Sat Oct 17 22:17:04 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886689, encodeId=ead688668900, content=g, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e855419670, createdName=ms4000001311767518, createdTime=Sat Sep 19 17:33:42 CST 2020, time=2020-09-19, status=1, ipAttribution=)]
    2020-10-17 ms2000001622015603

    积分

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=977501, encodeId=1a139e750161, content=想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ed95476566, createdName=ms2000000663115913, createdTime=Mon Jun 28 09:37:33 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977500, encodeId=70879e7500df, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ed95476566, createdName=ms2000000663115913, createdTime=Mon Jun 28 09:37:03 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892726, encodeId=39d8892e2681, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/ce079fd0944b4af0896c4bdb2d547ac3/73f2f6c2202b43ceb43dd2354f7f73e6.jpg, createdBy=dfab5426678, createdName=ms2000001622015603, createdTime=Sat Oct 17 22:17:04 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886689, encodeId=ead688668900, content=g, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e855419670, createdName=ms4000001311767518, createdTime=Sat Sep 19 17:33:42 CST 2020, time=2020-09-19, status=1, ipAttribution=)]
    2020-09-19 ms4000001311767518

    g

    0